Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Lilly Offers Free Testing for Novel Compounds

publication date: Jun 16, 2009
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Eli Lilly has taken another step in transforming itself from a fully integrated big pharma to a partnership arrangement, which it now calls a Fully Integrated Pharmaceutical Network (FIPNet). The goal is to foster open collaboration between Lilly and global laboratory researchers. Lilly calls its new program the Phenotypic Drug Discovery Initiative, or PD2 (pronounced PD-squared). Lilly is offering a free-of-charge use to outside researchers of its disease-state assays, complete with a secure web portal, which will evaluate the therapeutic potential of externally-developed synthesized compounds. More details...

Stock Symbol: (NYSE: LLY)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...